The all-or-nothing strategy has landed the ‘pride of the pharmaceutical industry' in a situation that deteriorated rapidly.

Starboard Value LP underperformed peers in 2024, a year in which Jeff Smith’s activist firm was frustrated with large ...

Pfizer on Monday named the former head of the U.S. health regulator's drug evaluation unit, Patrizia Cavazzoni, as its chief ...

Medicare changes will cut $1 billion from 2025 revenue, with Pfizer now responsible for 20% of catastrophic drug costs. Read ...

Director nominees with CEO experience have long featured in Board slates put forward by activist investors. Those candidates were typically from outs ...

Jeffrey Smith’s Starboard Value disclosed in an SEC filing its holdings as of December 31, 2024. The fund’s new buys during the fourth quarter ...

On another note, activist investor Starboard Value LP refrained from nominating directors to Pfizer's board before the January 25 deadline for the company's annual meeting. However, Starboard, who ...

Jefferies analyst Akash Tewari increased the price target for Pfizer (NYSE:PFE) shares from $33.00 to $34.00, while reiterating a Buy rating on the stock. Currently trading at $25.72, near its 52-week ...

That drug came through Pfizer’s 2022 acquisition of Global Blood Therapeutics for US$5.4bil, one of a string of purchases that Starboard considers to have delivered poor results, the person said.

Pfizer shares were last up 4.9% at US$48.25, climbing as high as $48.57 during the session. The stock's previous intraday high was $47.44, reached on April 12, 1999. Already a subscriber?

As well as, falling in tandem with the release of Pfizer’s annual earnings report, which reflected revenues of $63.6 billion. In the announcement, Bourla stated: “I’m excited for what’s ...

(Reuters) -Starboard Value has nominated four directors to the board of consumer products maker Kenvue (NYSE:KVUE), months after the activist investor criticized lackluster performance in a core ...